TNXP

Tonix Pharmaceuticals Holding Corp (TNXP) | Rumor.io

Tonix Pharmaceuticals Holding

TNXP

Attention (50-day avg)0.01%

Attention rank (50-day avg)#400

Bullish sentiment (50-day avg)82%

Price to earnings ratio0.05

Market capitalization169.6M

Earnings per share-13.1

Dividend yield (TTM)—

Revenue (annual)13.1M

Net income (annual)-124M

Social

What share of all stock conversation is about TNXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.18	0.03% +0.02	0.01% 0	0.01% -0.01

Sep 29

Tonix Pharmaceuticals' stock has been a subject of discussion, with some investors expressing regret and frustration with the company's performance.
The stock's price has been volatile, with some investors hoping for a turnaround and others expressing skepticism.
Tonix Pharmaceuticals' product has been noted as having the potential to save lives, which may have contributed to the company's market value.

Generated by AI

Sentiment

Of the messages about TNXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +3.03	72.85% -7.44	83.33% +3.94	84.49% -1
Bearish	33.33% -3.03	27.15% +7.44	16.67% -3.94	15.51% +1

Bullish· Sep 29

Tonix Pharmaceuticals Holding Corp. has demonstrated strength in its ability to outperform hedge funds that invested in the stock, with a notable 30% increase in value after a previous surge.
The company's product has shown potential in saving lives, and the stock has formed a golden cross, indicating a bullish longer-term bias and a potential breakout.
The stock has broken a key resistance level with a surge in volume, and the RSI has exited oversold territory, suggesting a low-risk long opportunity, with the 50MA serving as dynamic support on pullbacks.

Bearish· Sep 24

The company's stock has lost 60%+ of its value, with some investors expecting it to crash below $9.
The CEO, Seth, has been criticized for his management style, with some calling him a "sociopath" and a "bloodsucker" who is ruining families and destroying investors' portfolios.
The company has a history of poor performance, with some investors warning that it will be "shorted to oblivion" and that the only way back is another reverse stock split (RS), which would be the fourth such move.

Generated by AI

Topics

Of the messages about TNXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	69.57%	57.56%	35.2%
Technical Analysis	100%	30.43%	28.29%	11.9%
Earnings	0%	0%	5.37%	2.43%
Macro	0%	0%	6.34%	25.95%
Analysts	0%	0%	1.46%	24.06%
Controversies	0%	0%	0.98%	0.46%

Announcements· Jun 8

Tonix Pharmaceuticals Holding Corp. (TNXP) has secured a second commercial payer agreement for its drug TONMYA, expanding coverage to approximately 17 million U.S. commercial lives, bringing total commercial coverage to around 52 million lives.
TONMYA, a cyclobenzaprine HCl sublingual tablet and first new fibromyalgia medicine for adults in over 15 years approved by the FDA, has Medicaid coverage in most states representing around 75 million lives.
The company's TONMYA Together Support Program offers savings for eligible commercially insured patients, and the agreement with the second GPO is expected to speed up the conversion of bridge scripts to paid scripts, leading to exponential growth in prescription and revenue.

Technical Analysis· Mar 19

$TNXP is in a trend line break scenario, with a key resistance level at $16.90 and a support level at $16.35.
$TNXP is being compared to a 9 EMA (short-term moving average), which is a common technical analysis indicator.
The stock's strategy includes buying between $13.80 and $14.50, with a stop loss at $12.50 and target prices of $18.00-$20.00 and $20.00-$22.00.

Generated by AI

Community

Of the messages about TNXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.1%	25.07%	61.14%	73.25%
Newcomers	11.9%	74.93%	38.86%	26.75%

Regulars· Sep 29

The stock has reached a 52-week low, and the author is waiting for a response from Seth to say something about the potential for a rebound.
The author is advocating for patience, referencing a previous 30% increase in the stock price after a two-month wait.
The author is expressing frustration with the company's guidance, specifically the absence of a POS CEO, and the stock's impact on their personal finances.

Newcomers· Sep 29

The price of TNXP has been breaking through resistance and is showing signs of a bullish trend, with some analysts suggesting a potential increase to $12 or more.
The company's market capitalization is $160 million, which is relatively small compared to other companies in the industry.
Technical indicators such as the golden cross, MACD bullish crossover, and rising RSI are all suggesting a positive momentum for TNXP, but some analysts are cautioning that a pullback to trendline support or a retest of new support could be a low-risk opportunity for long entries.

Generated by AI

New agreement, effective immediately, adds approximately 21 million Medicare lives (38% of approximately 55 million Medicare lives in the U.S.) Commercial and government payer coverage for TONMYA now reaches approximately 166 million covered lives (53% of total U.S. lives) BERKELEY HEIGHTS, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced a second

8d agoYahoo Finance

Raymond James reiterates Strong Buy on Tonix Pharma stock at $27

8d agoInvesting.com

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman told attendees at the Cantor Healthcare Conference that the company’s near-term focus is the commercial launch of TONMYA, its FDA-approved treatment for fibromyalgia in adults, while it advances development programs in Lyme disease prevention and

18d agoYahoo Finance

Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push

19d agoInvesting.com

Tonix Pharma Appoints New Chief Commercial Officer

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

20d agoThe Globe and Mail

Also Discussed

Investors talking about TNXP also mention

#	Name	Attention
1	iBio, Inc.IBIO	0%0
2	YTEN - Yield10 Bioscience, Inc.	——
3	TTNP - Titan Pharmaceuticals, Inc.	——
4	Bio-Path Holdings Inc.BPTH	0%0
5	Moleculin Biotech, Inc.MBRX	0%0
6	Grace Therapeutics Inc.ACST	0%0
7	BIOL - BIOLASE, Inc.	——
8	EVOK - Evoke Pharma, Inc.	——
9	Jaguar Health, Inc.JAGX	0.02%-0.02
10	Onconova Therapeutics IncONTX	0%0

Tonix Pharmaceuticals Holding Corp

Healthcare
Biotechnology

Tonix Pharmaceuticals Holding Corp. is a fully integrated, commercial-stage biopharmaceutical company focused on developing, licensing, and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its primary emphasis is on central nervous system (CNS) disorders, including fibromyalgia and major depressive disorder, addressed by product candidates like TNX-102 SL, a sublingual cyclobenzaprine HCl tablet branded as TONMYA, now available by prescription as the first new FDA-approved fibromyalgia treatment in over 15 years. The company also markets Zembrace SymTouch and Tosymra for acute migraine treatment in adults. In immunology, it advances biologics such as TNX-1500, a humanized monoclonal antibody targeting CD40-ligand for organ transplant rejection, autoimmunity, and cancer. Additional pipelines cover infectious diseases like mpox and Lyme disease prevention with TNX-801 and TNX-4800, respectively, rare diseases including Prader-Willi Syndrome via TNX-2900, and other areas. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals Holding Corp. operates in the biotechnology sector, targeting unmet medical needs across multiple therapeutic domains.

Website

Location

200 Connell Drive

Berkeley Heights, NJ, 07928

United States

Social

What share of all stock conversation is about TNXP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.18	0.03% +0.02	0.01% 0	0.01% -0.01

Sep 29

Tonix Pharmaceuticals' stock has been a subject of discussion, with some investors expressing regret and frustration with the company's performance.
The stock's price has been volatile, with some investors hoping for a turnaround and others expressing skepticism.
Tonix Pharmaceuticals' product has been noted as having the potential to save lives, which may have contributed to the company's market value.

Generated by AI

Sentiment

Of the messages about TNXP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	66.67% +3.03	72.85% -7.44	83.33% +3.94	84.49% -1
Bearish	33.33% -3.03	27.15% +7.44	16.67% -3.94	15.51% +1

Bullish· Sep 29

Tonix Pharmaceuticals Holding Corp. has demonstrated strength in its ability to outperform hedge funds that invested in the stock, with a notable 30% increase in value after a previous surge.
The company's product has shown potential in saving lives, and the stock has formed a golden cross, indicating a bullish longer-term bias and a potential breakout.
The stock has broken a key resistance level with a surge in volume, and the RSI has exited oversold territory, suggesting a low-risk long opportunity, with the 50MA serving as dynamic support on pullbacks.

Bearish· Sep 24

The company's stock has lost 60%+ of its value, with some investors expecting it to crash below $9.
The CEO, Seth, has been criticized for his management style, with some calling him a "sociopath" and a "bloodsucker" who is ruining families and destroying investors' portfolios.
The company has a history of poor performance, with some investors warning that it will be "shorted to oblivion" and that the only way back is another reverse stock split (RS), which would be the fourth such move.

Generated by AI

Topics

Of the messages about TNXP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	69.57%	57.56%	35.2%
Technical Analysis	100%	30.43%	28.29%	11.9%
Earnings	0%	0%	5.37%	2.43%
Macro	0%	0%	6.34%	25.95%
Analysts	0%	0%	1.46%	24.06%
Controversies	0%	0%	0.98%	0.46%

Announcements· Jun 8

Tonix Pharmaceuticals Holding Corp. (TNXP) has secured a second commercial payer agreement for its drug TONMYA, expanding coverage to approximately 17 million U.S. commercial lives, bringing total commercial coverage to around 52 million lives.
TONMYA, a cyclobenzaprine HCl sublingual tablet and first new fibromyalgia medicine for adults in over 15 years approved by the FDA, has Medicaid coverage in most states representing around 75 million lives.
The company's TONMYA Together Support Program offers savings for eligible commercially insured patients, and the agreement with the second GPO is expected to speed up the conversion of bridge scripts to paid scripts, leading to exponential growth in prescription and revenue.

Technical Analysis· Mar 19

$TNXP is in a trend line break scenario, with a key resistance level at $16.90 and a support level at $16.35.
$TNXP is being compared to a 9 EMA (short-term moving average), which is a common technical analysis indicator.
The stock's strategy includes buying between $13.80 and $14.50, with a stop loss at $12.50 and target prices of $18.00-$20.00 and $20.00-$22.00.

Generated by AI

Community

Of the messages about TNXP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	88.1%	25.07%	61.14%	73.25%
Newcomers	11.9%	74.93%	38.86%	26.75%

Regulars· Sep 29

The stock has reached a 52-week low, and the author is waiting for a response from Seth to say something about the potential for a rebound.
The author is advocating for patience, referencing a previous 30% increase in the stock price after a two-month wait.
The author is expressing frustration with the company's guidance, specifically the absence of a POS CEO, and the stock's impact on their personal finances.

Newcomers· Sep 29

The price of TNXP has been breaking through resistance and is showing signs of a bullish trend, with some analysts suggesting a potential increase to $12 or more.
The company's market capitalization is $160 million, which is relatively small compared to other companies in the industry.
Technical indicators such as the golden cross, MACD bullish crossover, and rising RSI are all suggesting a positive momentum for TNXP, but some analysts are cautioning that a pullback to trendline support or a retest of new support could be a low-risk opportunity for long entries.

Generated by AI

Tonix Pharmaceuticals Holding

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 24

Announcements· Jun 8

Technical Analysis· Mar 19

Regulars· Sep 29

Newcomers· Sep 29

Tonix expands Medicare coverage for fibromyalgia drug TONMYA

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Raymond James reiterates Strong Buy on Tonix Pharma stock at $27

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push

Tonix Pharma Appoints New Chief Commercial Officer

Also Discussed

Tonix Pharmaceuticals Holding Corp

Company Information

Location

Tonix expands Medicare coverage for fibromyalgia drug TONMYA

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

Raymond James reiterates Strong Buy on Tonix Pharma stock at $27

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push

Tonix Pharma Appoints New Chief Commercial Officer

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 24

Announcements· Jun 8

Technical Analysis· Mar 19

Regulars· Sep 29

Newcomers· Sep 29